Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients

Journal of Clinical Lipidology

Volumn 7, Issue 5, 2013, Pages 414-422

  Franceschini, Guido ^a   Favari, Elda ^b   Calabresi, Laura ^a   Simonelli, Sara ^a   Bondioli, Alighiero ^a   Adorni, Maria Pia ^b   Zimetti, Francesca ^b   Gomaraschi, Monica ^a   Coutant, Karine ^c   Rossomanno, Simona ^c   Niesor, Eric J ^c   Bernini, Franco ^b   Benghozi, Renee ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cholesterol efflux capacity; Cholesteryl ester transfer protein; Fenofibrate; High density lipoprotein cholesterol; Niacin

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; EXTENDED RELEASE NIACIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHO CELL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; LIVER CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

CRICETULUS GRISEUS;

CHOLESTEROL EFFLUX CAPACITY; CHOLESTERYL ESTER TRANSFER PROTEIN; FENOFIBRATE; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; NIACIN;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOLOGICAL TRANSPORT; CHO CELLS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CRICETINAE; CRICETULUS; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NIACIN; PARTICLE SIZE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SAFETY; TRIGLYCERIDES; YOUNG ADULT;

EID: 84885022315     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.06.007     Document Type: Article

References (39)

1. C. Baigent, A. Keech, P.M. Kearney, and et al Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267-128
2. W.P. Castelli, M.D.K. Anderson, P.W.F. Wilson, and D. Levy Lipids and risk of coronary heart disease: the Framingham Study Ann Epidemiol 2 1992 23 28
3. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, and et al Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
4. D.J. Gordon, J.L. Probstfield, R.J. Garrison, and et al Major lipids, apolipoproteins, and risk of vascular disease: high-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15
5. M. Briel, I. Ferreira-Gonzalez, J.J. You, and et al Association between charge in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92
6. M.J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin and cholesteryl ester transfer protein inhibitors Eur Heart J 31 2010 149 164
7. S.C. Smith Jr., J. Allen, S.N. Blair, and et al AHA/ACC guideline for the secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
8. G.L. Vega, and S.M. Grundy Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia Arch Intern Med 154 1994 73 82
9. R.H. Knopp, P. Alagona, K.B. Davidson, and et al Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the treatment of hyperlipidemia Metabolism 47 1998 1097 1104
10. N. Khoury The use of fibric acid derivatives in cardiovascular prevention Curr Treat Options Cardiovasc Med 13 2011 335 342
11. P.G. Yancey, A.E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M.C. Phillips, and G.H. Rothblat Importance of different pathways of cellular cholesterol efflux Arterioscler Thromb Vasc Biol 23 2003 712 719
12. A.V. Khera, M. Cuchel, M. de la Llera-Moya, and et al Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
13. L. Calabresi, M. Gomaraschi, and G. Franceschini High-density lipoprotein quantity or quality for cardiovascular prevention? Curr Pharm Des 16 2010 1494 1503
14. G.H. Rothblat, M. de la Llera-Moya, E. Favari, P.G. Yancey, and G. Kellner-Weibel Cellular cholesterol flux studies: methodological considerations Atherosclerosis 163 2002 1 8
15. E. Favari, L. Calabresi, M.P. Adorni, and et al Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1 Biochemistry 48 2009 11067 11074
16. W. Jessup, I.C. Gelissen, K. Gaus, and L. Kritharides Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages Curr Opin Lipidol 17 2006 247 257
17. L. Calabresi, E. Favari, E. Moleri, and et al Functional LCAT is not required for macrophage cholesterol efflux to human serum Atherosclerosis 204 2009 141 146
18. T. Miyazaki, K. Shimada, K. Miyauchi, and et al Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting Lipids Health Dis 9 2010 121 130
19. A. Kontush, and M.J. Chapman Antiatherogenic small, dense HDL: guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3 2006 144 153
20. H. Jafri, A.A. Alsheikh-Ali, P. Mooney, C.D. Kimmelstiel, R.H. Karas, and J.T. Kuvin Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD J Clin Lipidol 3 2009 45 50
21. R.H. Superko Lipoprotein subclasses and atherosclerosis Front Biosci 6 2001 D355 D365
22. J.M. Morgan, D.M. Capuzzi, R.I. Baksh, and et al Effects of extended-release niacin on lipoprotein subclass distribution Am J Cardiol 91 2003 1432 1436
23. K. El Harchaoui, B.J. Arsenault, R. Franssen, and et al High-density lipoprotein particle size and concentration and coronary risk Ann Intern Med 150 2009 84 93
24. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
25. S. Parish, A. Offer, R. Clarke, and et al Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study Circulation 125 2012 2469 2478
26. A. Kontush, and M.J. Chapman Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities Curr Opin Lipidol 21 2010 312 318
27. L. Yvan-Charvet, J. Kling, T. Pagler, and et al Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler Thromb Vasc Biol 30 2010 1430 1438
28. G. Franceschini, L. Calabresi, C. Colombo, E. Favari, F. Bernini, and C.R. Sirtori Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients Atherosclerosis 195 2007 385 391
29. T. Rubic, M. Trottmann, and R.L. Lorenz Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin Biochem Pharm 67 2004 411 419
30. M. Ogata, M. Tsujita, M.A. Hossain, and et al On the mechanism for PPAR agonists to enhance ABCA1 gene expression Atherosclerosis 205 2009 413 419
31. M. Lukasova, C. Malaval, A. Gille, J. Kero, and S. Offermanns Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells J Clin Invest 121 2011 1163 1173
32. R. Penn, R.X., Williams III, D.K. Guha-Ray, W.G. Sawyers, S.L. Braun, and K.T. Rains An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers Clin Ther 28 2006 45 54
33. R.M. Menon, M.H. Adams, M.A. González, D.S. Tolbert, J.H. Leu, and E.A. Cefali Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation Int J Clin Pharmacol Ther 45 2007 448 454
34. H. Ohmura, H. Mokuno, M. Sawano, and et al Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible increased risk of coronary artery disease in subjects with phenotype B Metabolism 51 2002 1081 1087
35. S. Yla-Herttuala Oxidised LDL and atherosclerosis Ann N Y Acad Sci 874 1999 134 137
36. J. McKenney, H. Bays, M. Koren, and et al Safety of extended-release niacin/laropiprant in patients with dyslipidemia J Clin Lipidol 4 2010 105 112
37. The AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, and et al Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
38. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
39. S.J. Nicholls Is niacin ineffective? Or did AIM-HIGH miss its target? Cleveland Clinic J Med 79 2012 38 43